z-logo
open-access-imgOpen Access
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer
Author(s) -
Jacopo Giuliani,
Andrea Bonetti
Publication year - 2021
Publication title -
cancer drug resistance
Language(s) - English
Resource type - Journals
ISSN - 2578-532X
DOI - 10.20517/cdr.2021.14
Subject(s) - osimertinib , epidermal growth factor receptor , lung cancer , drug resistance , drug , cancer research , gene , epidermal growth factor , medicine , biology , cancer , receptor , oncology , pharmacology , genetics , erlotinib

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom